JohnMoehrke SLS ValueSets Implementation Guide
0.1.0 - ci-build International flag

JohnMoehrke SLS ValueSets Implementation Guide, published by John Moehrke. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/JohnMoehrke/SLSValueSets/ and changes regularly. See the Directory of published versions

ValueSet: clinical codes that indicate HIV

Official URL: http://johnmoehrke.github.io/SLSValueSets/ValueSet/SamhsaSensitiveHIV Version: 0.1.0
Active as of 2016-09-09 Computable Name: SamhsaSensitiveHIV
Other Identifiers: OID:1.3.6.1.4.1.66281.18.48.14

Usage:Clinical Focus: HIV/AIDS information sensitivity

HIV/AIDS information

  • SAMHSA C2S HIV/AIDS Information
    • ValueSet 2.16.840.1.113762.1.4.1142.23 // HCPCS
    • ValueSet 2.16.840.1.113762.1.4.1142.24 // ICD9CM
    • ValueSet 2.16.840.1.113762.1.4.1142.25 // LOINC
    • ValueSet 2.16.840.1.113762.1.4.1142.26 // RXNORM
    • ValueSet 2.16.840.1.113762.1.4.1142.27 // SNOMED-CT
    • ValueSet 2.16.840.1.113762.1.4.1142.60 // CPT
  • SAMHSA Test C2S HIV/AIDS Information Sensitivity
    • ValueSet 2.16.840.1.113762.1.4.1142.67 // SNOMEDCD

References

This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)

Logical Definition (CLD)

This value set includes codes based on the following rules:

 

Expansion

This value set contains 116 concepts

SystemCodeDisplay (en)JSONXML
http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets  G0432Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening
http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets  G0433Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening
http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets  G0435Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening
http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets  G8491I intend to report the hiv/aids measures group
http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets  G8500All quality actions for the applicable measures in the hiv/aids measures group have been performed for this patient
http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets  S3645Hiv-1 antibody testing of oral mucosal transudate
http://hl7.org/fhir/sid/icd-9-cm  136.3Pneumocystosis
http://hl7.org/fhir/sid/icd-9-cm  176.9Kaposi's sarcoma, unspecified site
http://hl7.org/fhir/sid/icd-9-cm  42Operations on esophagus
http://loinc.org  10901-7HIV 2 gp125 Ab [Presence] in Serum by Immunoblot
http://loinc.org  10902-5HIV 2 gp36 Ab [Presence] in Serum by Immunoblot
http://loinc.org  11078-3HIV 2 gp80 Ab [Presence] in Serum by Immunoblot
http://loinc.org  11079-1HIV 2 p26 Ab [Presence] in Serum by Immunoblot
http://loinc.org  11080-9HIV 2 p53 Ab [Presence] in Serum by Immunoblot
http://loinc.org  11081-7HIV 2 p56 Ab [Presence] in Serum by Immunoblot
http://loinc.org  11082-5HIV 2 p68 Ab [Presence] in Serum by Immunoblot
http://loinc.org  13920-4HIV 2 p41 Ab [Presence] in Serum by Immunoblot
http://loinc.org  21334-8HIV 2 gp105 Ab [Presence] in Serum by Immunoblot
http://loinc.org  21335-5HIV 2 gp120 Ab [Presence] in Serum by Immunoblot
http://loinc.org  21336-3HIV 2 gp15 Ab [Presence] in Serum by Immunoblot
http://loinc.org  21337-1HIV 2 gp34 Ab [Presence] in Serum by Immunoblot
http://loinc.org  21338-9HIV 2 p31 Ab [Presence] in Serum by Immunoblot
http://loinc.org  21339-7HIV 2 p55 Ab [Presence] in Serum by Immunoblot
http://loinc.org  21340-5HIV 2 p58 Ab [Presence] in Serum by Immunoblot
http://loinc.org  22358-6HIV 2 Ab [Units/volume] in Serum
http://loinc.org  25841-8HIV 2 proviral DNA [Presence] in Blood by NAA with probe detection
http://loinc.org  25842-6HIV 2 proviral DNA [Presence] in Specimen by NAA with probe detection
http://loinc.org  30361-0HIV 2 Ab [Presence] in Serum or Plasma by Immunoassay
http://loinc.org  31073-0HIV 2 Ab band pattern [Interpretation] in Serum by Immunoblot
http://loinc.org  33806-1HIV 2 IgG Ab [Presence] in Serum by Immunoblot
http://loinc.org  33807-9HIV 2 IgG Ab [Presence] in Serum
http://loinc.org  34699-9HIV 2 proviral DNA [Presence] in Serum or Plasma by NAA with probe detection
http://loinc.org  42768-2HIV 1 and 2 Ab [Interpretation] in Serum Narrative
http://loinc.org  43185-8HIV 1 and 2 Ab band pattern [Interpretation] in Serum by Immunoblot
http://loinc.org  45212-8HIV 2 p31+p34 Ab [Presence] in Serum by Immunoblot
http://loinc.org  47029-4HIV 2 Ab [Presence] in Cerebral spinal fluid by Immunoblot
http://loinc.org  51786-2HIV 2 Ab Signal/Cutoff in Serum or Plasma by Immunoassay
http://loinc.org  5224-1HIV 2 Ab [Units/volume] in Serum or Plasma by Immunoassay
http://loinc.org  5225-8HIV 2 Ab [Presence] in Serum by Immunoblot
http://loinc.org  56888-1HIV 1+2 Ab+HIV1 p24 Ag [Presence] in Serum or Plasma by Immunoassay
http://loinc.org  57976-3HIV 2 gp140 Ab [Presence] in Serum by Immunoblot
http://loinc.org  57977-1HIV 2 p16 Ab [Presence] in Serum by Immunoblot
http://loinc.org  57978-9HIV 2 p34 Ab [Presence] in Serum by Immunoblot
http://loinc.org  58900-2HIV 1+2 Ab+HIV1 p24 Ag [Units/volume] in Serum or Plasma by Immunoassay
http://loinc.org  62456-9HIV 2 p15 Ab [Presence] in Serum by Immunoblot
http://loinc.org  6429-5HIV identified in Blood by Organism specific culture
http://loinc.org  6430-3HIV identified in Semen by Organism specific culture
http://loinc.org  6431-1HIV identified in Specimen by Organism specific culture
http://loinc.org  69353-1HIV 2 RNA [Presence] in Serum or Plasma by NAA with probe detection
http://loinc.org  69354-9HIV 2 RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
http://loinc.org  69668-2HIV 1 and 2 Ab [Identifier] in Serum or Plasma by Rapid immunoassay
http://loinc.org  7919-4HIV 2 Ab [Presence] in Serum
http://loinc.org  9836-8HIV proviral DNA [Presence] in Blood by Probe with amplification
http://loinc.org  LP14307-0HIV 1
http://loinc.org  LP16715-2HIV 1+2
http://loinc.org  LP16716-0HIV 2
http://loinc.org  LP29063-2HIV reverse transcriptase gene
http://loinc.org  LP30901-0HIV protease gene
http://loinc.org  LP32723-6HIV reverse transcriptase+protease gene
http://loinc.org  LP36650-7HIV 1 & 2
http://loinc.org  LP36876-8HIV nucleoside reverse transcriptase gene
http://loinc.org  LP36877-6HIV nonnucleoside reverse transcriptase gene
http://loinc.org  LP38459-1HIV 1+2 Ab
http://loinc.org  LP38463-3HIV 2 Ab
http://loinc.org  LP62411-1HIV 1+O+2 Ab
http://www.nlm.nih.gov/research/umls/rxnorm  152535Zovirax
http://www.nlm.nih.gov/research/umls/rxnorm  281acyclovir
http://snomed.info/sct  111880001Acute HIV infection
http://snomed.info/sct  420721002Acquired immunodeficiency syndrome-associated disorder
http://www.ama-assn.org/go/cpt  0575FHIV RNA control plan of care, documented (HIV)
http://www.ama-assn.org/go/cpt  3292FHIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr)
http://www.ama-assn.org/go/cpt  3490FHistory of AIDS-defining condition (HIV)
http://www.ama-assn.org/go/cpt  3491FHIV indeterminate (infants of undetermined HIV status born of HIV-infected mothers) (HIV)
http://www.ama-assn.org/go/cpt  3492FHistory of nadir CD4+ cell count <350 cells/mm3 (HIV)
http://www.ama-assn.org/go/cpt  3493FNo history of nadir CD4+ cell count <350 cells/mm3 and no history of AIDS-defining condition (HIV)
http://www.ama-assn.org/go/cpt  3494FCD4+ cell count <200 cells/mm3 (HIV)
http://www.ama-assn.org/go/cpt  3495FCD4+ cell count 200 - 499 cells/mm3 (HIV)
http://www.ama-assn.org/go/cpt  3496FCD4+ cell count >=500 cells/mm3 (HIV)
http://www.ama-assn.org/go/cpt  3497FCD4+ cell percentage <15% (HIV)
http://www.ama-assn.org/go/cpt  3498FCD4+ cell percentage >=15% (HIV)
http://www.ama-assn.org/go/cpt  3500FCD4+ cell count or CD4+ cell percentage documented as performed (HIV)
http://www.ama-assn.org/go/cpt  3502FHIV RNA viral load below limits of quantification (HIV)
http://www.ama-assn.org/go/cpt  3503FHIV RNA viral load not below limits of quantification (HIV)
http://www.ama-assn.org/go/cpt  3510FDocumentation that tuberculosis (TB) screening test performed and results interpreted (HIV) (IBD)
http://www.ama-assn.org/go/cpt  3511FChlamydia and gonorrhea screenings documented as performed (HIV)
http://www.ama-assn.org/go/cpt  3512FSyphilis screening documented as performed (HIV)
http://www.ama-assn.org/go/cpt  3513FHepatitis B screening documented as performed (HIV)
http://www.ama-assn.org/go/cpt  3514FHepatitis C screening documented as performed (HIV)
http://www.ama-assn.org/go/cpt  3515FPatient has documented immunity to Hepatitis C (HIV)
http://www.ama-assn.org/go/cpt  4149FHepatitis B vaccine injection administered or previously received (HEP-C, HIV) (IBD)
http://www.ama-assn.org/go/cpt  4270FPatient receiving potent antiretroviral therapy for 6 months or longer (HIV)
http://www.ama-assn.org/go/cpt  4271FPatient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV)
http://www.ama-assn.org/go/cpt  4274FInfluenza immunization administered or previously received (HIV) (P-ESRD)
http://www.ama-assn.org/go/cpt  4276FPotent antiretroviral therapy prescribed (HIV)
http://www.ama-assn.org/go/cpt  4279FPneumocystis jiroveci pneumonia prophylaxis prescribed (HIV)
http://www.ama-assn.org/go/cpt  4280FPneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (HIV)
http://www.ama-assn.org/go/cpt  4290FPatient screened for injection drug use (HIV)
http://www.ama-assn.org/go/cpt  4293FPatient screened for high-risk sexual behavior (HIV)
http://www.ama-assn.org/go/cpt  86689Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)
http://www.ama-assn.org/go/cpt  86701Antibody; HIV-1
http://www.ama-assn.org/go/cpt  86702Antibody; HIV-2
http://www.ama-assn.org/go/cpt  86703Antibody; HIV-1 and HIV-2, single result
http://www.ama-assn.org/go/cpt  87389Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result
http://www.ama-assn.org/go/cpt  87390Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1
http://www.ama-assn.org/go/cpt  87391Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-2
http://www.ama-assn.org/go/cpt  87534Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique
http://www.ama-assn.org/go/cpt  87535Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed
http://www.ama-assn.org/go/cpt  87536Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed
http://www.ama-assn.org/go/cpt  87537Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique
http://www.ama-assn.org/go/cpt  87538Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed
http://www.ama-assn.org/go/cpt  87539Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed
http://www.ama-assn.org/go/cpt  87900Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics
http://www.ama-assn.org/go/cpt  87901Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions
http://www.ama-assn.org/go/cpt  87903Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested
http://www.ama-assn.org/go/cpt  87904Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure)
http://www.ama-assn.org/go/cpt  87906Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion)

Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance)
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code

History

DateActionAuthorVerifierComment
2023-01-31reviseJohn MoehrkeAdministrative touchup to add history
2022-07-27createJohn MoehrkeJohn F. MoehrkeInitial ValueSet as per the C2S layout